导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.13% | 2387/4773 |
| 近一周 | -0.97% | 1451/5465 |
| 近一月 | -7.88% | 4712/5421 |
| 近一季 | 17.92% | 75/5231 |
| 近半年 | 2.51% | 1041/4920 |
| 近一年 | -15.18% | 3707/4394 |
| 近两年 | 23.59% | 2562/2954 |
| 近三年 | -17.79% | 2129/2253 |
| 成立以来 | -38.69% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.82% 2503/4961 |
-4.99% 3537/5312 |
- - |
- - |
| 2025 | 5.47% 2997/4813 |
0.43% 1854/3635 |
1.46% 2321/4076 |
20.09% 2034/4524 |
-13.81% 4315/4813 |
| 2024 | -22.88% 2533/3463 |
-17.21% 2574/2808 |
-12.52% 2605/3014 |
20.32% 729/3129 |
-11.51% 3040/3463 |
| 2023 | -20.17% 1866/2656 |
-6.76% 2169/2280 |
-15.24% 2248/2385 |
3.12% 198/2515 |
-2.03% 411/2655 |
| 2022 | -27.12% 1457/2207 |
-9.90% 365/1919 |
-3.47% 1821/2016 |
-23.01% 1951/2113 |
8.84% 254/2208 |
| 2021 | -11.12% 1103/1822 |
-1.20% 449/1255 |
17.59% 183/1330 |
-13.13% 1331/1466 |
-11.94% 1618/1822 |
| 2020 | 70.68% 71/1250 |
16.42% 1/1028 |
42.60% 3/1067 |
3.57% 978/1164 |
-0.74% 1084/1184 |
| 2019 | 56.36% 65/1092 |
32.14% 179/754 |
-3.66% 405/804 |
14.90% 18/850 |
6.89% 527/918 |
| 2018 | -20.90% 203/834 |
- - |
- - |
- - |
-18.82% 658/691 |
| 2017 | 7.46% 319/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.88% 332/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商国证生物医药指数(LOF)A VS. 长安沪深300非周期A(740101) |